Haleon Pakistan

Haleon Pakistan Limited
Company typePublic
PSXHALEON
IndustryPharmaceutical
Headquarters,
Pakistan
Area served
Pakistan
Key people
RevenueRs. 39.648 billion (US$140 million)[1] (2024)
Rs. 4.578 billion (US$16 million)[1] (2024)
Total assetsRs. 21.8 billion (US$76 million)[1] (2024)
Total equityRs. 11.99 billion (US$42 million)[1] (2024)
Number of employees
450[1] (2024)
ParentHaleon
Websitewww.haleon.pk

Haleon Pakistan Limited (formerly GlaxoSmithKline Consumer Healthcare Pakistan Limited) is a Pakistani public limited company that manufactures and markets consumer healthcare products. It is a subsidiary of the global consumer healthcare company, Haleon plc. The company is headquartered in Karachi and its shares are traded on the Pakistan Stock Exchange.[2]

Haleon Pakistan's history is closely linked to its parent company's evolution. The global entity, Haleon plc, was formed through the combination of consumer healthcare businesses from GSK, Novartis and Pfizer over the last decade.

In 2015, GlaxoSmithKline Consumer Healthcare Pakistan Limited (GSKCH) was demerged from GlaxoSmithKline Pakistan Limited (GLAXO).[3] In 2016, GSKCH started operations as an independent company.[4] A year later, in 2017, GSKCH got listed on PSX.[4] GlaxoSmithKline Pakistan Limited continues to exist as a separate company.[5]

In Pakistan, the company, formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited, underwent a name change to Haleon Pakistan[6] to align with the new global identity of Haleon, which was itself listed as an independent company on the London and New York stock exchanges in July 2022.[7]

The company has its head office in Karachi and a manufacturing facility in Jamshoro, Sindh. It also maintains regional sales offices in Lahore, Islamabad and Multan. In July 2025 Haleon Pakistan announced plans to expand its export markets and increase production capacity at its Jamshoro plant.[8]

Its CEO is Qawi Naseer, and its chairperson is Farhan Muhammad Haroon.[9]

References

  1. ^ a b c d e "Haleon Pakistan Limited 2024 Annual Report" (PDF).
  2. ^ Research, B. R. (15 August 2025). "Haleon Pakistan Limited". Brecorder. Retrieved 16 August 2025.
  3. ^ "GLAXO: earnings in red". Business Recorder. 1 September 2022. Retrieved 3 November 2022.
  4. ^ a b "GLAXO: earnings in red". Business Recorder. 1 September 2022. Retrieved 3 November 2022.
  5. ^ "GSK Pakistan Annual Report 2024" (PDF).
  6. ^ Limited, Haleon Pakistan. "Our History - Haleon Pakistan". Haleon Pakistan Limited. Retrieved 17 August 2025. {{cite web}}: |last= has generic name (help)
  7. ^ "Prospectus" (PDF). GSK plc. p. 15. Archived from the original (PDF) on 1 June 2022. Retrieved 10 June 2022.
  8. ^ Hanif, Usman (24 July 2025). "Haleon invests $12m in Panadol". The Express Tribune. Retrieved 16 August 2025.
  9. ^ "HALEON - Stock quote for Haleon Pakistan Limited - Pakistan Stock Exchange (PSX)". dps.psx.com.pk. Retrieved 17 August 2025.